Glaucoma is the leading cause of irreversible blindness worldwide, but about 50% of affected people remain undiagnosed until the later stages, when vision loss may be irreversible.
Seonix Bio’s Newly Launched Saliva-Based Genetic Test Aims To Shed Light On Glaucoma Risk Assessment
Seonix launched SightScore, the first clinical polygenic risk score test for glaucoma available in the US, and plans to introduce more genetic-based tests for eye conditions such as macular degeneration.
